Welcome to our dedicated page for Cytosorbents news (Ticker: CTSO), a resource for investors and traders seeking the latest updates and insights on Cytosorbents stock.
CytoSorbents Corporation (NASDAQ: CTSO) develops life-saving blood purification technologies for critical care and cardiac surgery patients. This dedicated news hub provides investors and medical professionals with essential updates about the company’s clinical advancements, regulatory milestones, and strategic initiatives.
Access timely information on earnings reports, product launch announcements, and partnership developments related to CytoSorb® and other polymer adsorption therapies. Our curated collection includes press releases about clinical trial outcomes, European Union regulatory updates, and innovations in cytokine storm management.
Bookmark this page to monitor CTSO’s progress in advancing critical care solutions while staying informed about financial performance and market positioning. Check regularly for verified updates directly from corporate communications and trusted financial news sources.
CytoSorbents (NASDAQ: CTSO) presented new data from the STAR Registry at the EuroPCR 2024 conference. The study, involving 102 patients on ticagrelor undergoing CABG surgery with CytoSorb blood purification, showed no device-related adverse events and a 9.8% rate of severe bleeding. The data suggest CytoSorb may reduce the wait time for surgery, lowering bleeding risks compared to historical data. This research was a top five finalist for the best scientific abstract. The results could expand CytoSorb's market as ticagrelor's patent expires and generic options become available.
CytoSorbents reported unaudited financial results for the first quarter of 2024, showcasing a robust 14% increase in product sales year over year and a 22% sequential increase. The company's product gross margins improved to 76%, marking the highest quarter for core CytoSorb sales in nearly 3 years. Additionally, the STAR-T data presented at AATS supported a favorable benefit-to-risk profile of DrugSorb-ATR in CABG patients. CytoSorbents is on track for FDA De Novo and Health Canada submissions for DrugSorb-ATR in Q3 2024.
CytoSorbents announced a virtual Key Opinion Leader and Analyst-Investor Day to discuss the STAR-T pivotal trial results and real-world experience with antithrombotic drug removal in Europe. The event will focus on severe perioperative bleeding in heart surgery patients on blood thinners, including Brilinta®. Experts will present key findings from the STAR-T trial and real-world data in the pre-specified CABG population, addressing the challenges of coronary artery disease and heart attacks globally.
FAQ
What is the current stock price of Cytosorbents (CTSO)?
What is the market cap of Cytosorbents (CTSO)?
